NCT03416231 is a Phase 2 clinical trial of Apatinib in NSCLC, sponsored by Afﬁliated Hospital of North Sichuan Medical College.

Who is sponsoring NCT03416231?

NCT03416231 is sponsored by Afﬁliated Hospital of North Sichuan Medical College.

What drugs are being tested in NCT03416231?

Interventions in NCT03416231: Apatinib, Docetaxel.

Is NCT03416231 still recruiting?

NCT03416231 is currently status unknown. Last updated 31 January 2018.

Last reviewed 2018-01-31 · How we verify

NCT03416231

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Apatinib Plus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC)

Status unknown Phase 2 Last updated 31 January 2018

What this trial tests

Phase 2 trial testing Apatinib in NSCLC in 20 participants. Status unknown.

Timeline

30 November 2016

Primary endpoint
1 January 2019

1 January 2020

Quick facts

Lead sponsor	Afﬁliated Hospital of North Sichuan Medical College
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	30 November 2016
Primary completion	1 January 2019
Estimated completion	1 January 2020
Sites	1 location across China

Drugs / interventions tested

Apatinib (Apatinib) — full drug profile →
Docetaxel (Docetaxel) — full drug profile →

Conditions studied

NSCLC — all drugs for NSCLC →

Sponsor

Afﬁliated Hospital of North Sichuan Medical College

Who can join

18 and older, any sex, with NSCLC. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study was to evaluate the effectiveness and safety of apatinib combined with docetaxel in NSCLC.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer.
Qiang H, Chang Q, Xu J, Qian J, et al · · 2020 · cited 53× · PMID 32065262 · DOI 10.1007/s00432-020-03129-6
Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC: A multi center prospective study.
Jiang Q, Zhang NL, Ma DY, Tan BX, et al · · 2019 · cited 14× · PMID 31261514 · DOI 10.1097/md.0000000000016065

Verify or expand the search:

Other trials of Apatinib

Trials testing the same drug.

NCT07309419 — A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunothera · Phase 2, PHASE3 · not yet recruiting
NCT07334483 — A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC · Phase 2 · recruiting
NCT07031154 — A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Rese · Phase 2 · not yet recruiting
NCT07294664 — PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer · Phase 2 · recruiting
NCT06893887 — Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma · NA · recruiting

Other recruiting trials for NSCLC

Currently open trials in the same condition.

NCT07479277 — Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC · NA · recruiting
NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting
NCT07274813 — A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors · EARLY_PHASE1 · recruiting
NCT07325864 — Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site · recruiting
NCT07169552 — HC010 in First-line PD-L1 Positive Advanced NSCLC Patients · Phase 2 · recruiting

Other Afﬁliated Hospital of North Sichuan Medical College trials

Trials by the same sponsor.

NCT03588494 — Endostar in Combination With Chemoradiotherapy in Patient With Advanced Non-small Cell Lung Cancer · Phase 2, PHASE3 · unknown
NCT03798665 — A Real World Study Evaluating the Clinical Application of PEG-rhG-CSF During Chemotherapy in Patients With Solid Tumors · unknown
NCT04740840 — Anti Inflammatory Treatment of Hypertension · Phase 2, PHASE3 · completed
NCT04421274 — Bone Marrow Mesenchymal Stem Cells Transfer in Patients With ST-segment Elevation Myocardial Infarction · Phase 2, PHASE3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03416231 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Afﬁliated Hospital of North Sichuan Medical College
Last refreshed: 31 January 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03416231.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing